COYA

Coya Therapeutics' stock price has been influenced by several events. In November 2025, the company reported third-quarter financial results and received $4.2 million from Dr. Reddy's Laboratories. In January 2026, Coya announced an $11.1 million private placement. In March 2026, Coya reported fiscal year 2025 financial results, with increased collaboration revenue but a widened net loss, and announced the launch of the ALSTARS Phase 2 trial for COYA 302 in ALS and FDA acceptance of an IND application for COYA 302 for FTD. In April 2026, the company announced the publication of data supporting COYA 302 in ALS, leading to a stock increase, and a planned board transition. As of May 8, 2026, the stock price had fallen, and analysts gave Coya a consensus rating of 'Moderate Buy' with a $16.00 target price.